1. Search Result
Search Result
Results for "

CA1

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

3

Peptides

3

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16147

    Oxi4503; CA1P; Combretastatin A1 diphosphate

    Others Cancer
    Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors [1] .
    Combretastatin A1 phosphate
  • HY-139145

    Trimethylopropane phosphate

    GABA Receptor Neurological Disease
    Etbicyphat (Trimethylopropane phosphate) is a potent GABA(A) receptors competitive antagonist. Etbicyphat induces epileptiform activities in hippocampal CA1 neurons, and binds to the GABA(A)-benzodiazepine receptors [1].
    Etbicyphat
  • HY-B1424
    Benzthiazide
    1 Publications Verification

    Carbonic Anhydrase Cardiovascular Disease Cancer
    Benzthiazide is a long-acting diuretic [1] and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells .
    Benzthiazide
  • HY-RS01762

    Small Interfering RNA (siRNA) Others

    CA1 Human Pre-designed siRNA Set A contains three designed siRNAs for CA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CA1 Human Pre-designed siRNA Set A
    CA1 Human Pre-designed siRNA Set A
  • HY-14477

    PARP Neurological Disease
    UPF-1035 is a selective PARP-2 inhibitor with an IC50 value of 0.15 μM. UPF-1035 increases CA1 pyramidal cell loss in hippocampal and has neuroprotective activity [1].
    UPF-1035
  • HY-100843

    Others Neurological Disease
    L-AP6 is a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons [1].
    L-AP6
  • HY-117578

    Endogenous Metabolite Neurological Disease
    KB 5666 is a benzoxazine derivative with lipid peroxidation inhibitory activity. KB 5666 showed protective effects against post-ischemic neuronal death. KB 5666 effectively protected CA1 neurons when injected 5 minutes before or immediately after ischemia. KB 5666 also showed a dose-dependent protective effect when injected within 1 hour after ischemia. KB 5666 effectively prevented the significant decrease in microtubule-associated protein 2 immunoreactivity within the dendritic field of CA1 pyramidal cells. KB 5666 prevented the decrease in [3H]PDBu binding activity in different layers of the CA1 region after ischemia. The application of KB 5666 showed the ability to improve the cellular and functional consequences of ischemia [1].
    KB 5666
  • HY-I1070

    (R)-Isoleucine

    Others Neurological Disease
    D-Isoleucine ((R)-Isoleucine), an isoleucine stereoisomer, is a selective activator of Asc-1 antiporter, which enhances long-term potentiation at the hippocampal CA1-CA3 via release of endogenous D-serine [1].
    D-Isoleucine
  • HY-139145S

    Trimethylopropane phosphate-13C3

    GABA Receptor Neurological Disease
    Etbicyphat- 13C3 is the 13C labeled Etbicyphat (HY-139145). Etbicyphat is a potent GABA(A) receptors competitive antagonist. Etbicyphat induces epileptiform activities in hippocampal CA1 neurons, and binds to the GABA(A)-benzodiazepine receptors[1][2].
    Etbicyphat-13C3
  • HY-116143

    MAGL Metabolic Disease
    SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC50s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis [1].
    MAGL-IN-12
  • HY-N5130

    Others Neurological Disease
    Effusol, a phenolic constituent from Juncus effuses, exhibits potent scavenging activity for DPPH and ABTS radicals, with IC50 values of 79 μM and 2.73 μM, respectively. Effusol rescues CA1 LTP attenuated by corticosterone, defending the hippocampal function against stress-induced cognitive decline [1].
    Effusol
  • HY-136980

    Asp-Glu

    Endogenous Metabolite Neurological Disease
    Aspartylglutamate (Asp-Glu) is a dipeptide that exhibits excitatory activity, as it has been shown to depolarize CA1 pyramidal neurons and increase conductance in response to stimulation. Aspartylglutamate selectively binds to certain glutamate receptors and demonstrates potent effects in specific regions of the hippocampus, particularly in the stratum radiatum where it enhances excitatory neurotransmission.
    Aspartylglutamate
  • HY-116790

    (S)-Penbutolol; (-)-Isopenbutolol

    Adrenergic Receptor 5-HT Receptor Neurological Disease Endocrinology
    (-)-Penbutolol ((S)-Penbutolol) is a potent β-adrenoceptor and 5-HT receptor antagonist with Ki values of 11.6 nM and 11.9 nM for 5-HT in rat cornu ammonis 1 (CA1) and human CA3. (-)-Penbutolol can increase hippocampal 5-HT output [1] .
    (-)-Penbutolol
  • HY-P4397

    Oxytocin Receptor Endocrinology
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, an oxytocin receptor antagonist, abolishes oxytocin-enhanced inhibitory postsynaptic currents in CA1 pyramidal neurons [1].
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin
  • HY-10932

    Ro 13-5057

    nAChR iGluR Neurological Disease
    Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders [1] .
    Aniracetam
  • HY-106784A

    Others Neurological Disease
    (E)-Ajoene is a oxygenated ajoene and organosulfur compound, which can be acquired via allicin decomposing. The polysulfides from garlic can be converted by human red blood cells into hydrogen sulfide (H2S) and allyl glutathione. (E)-Ajoene has been proved to show neuroprotective effects against ischemic damage. (E)-Ajoene is orally active to inhibit lipid peroxidation. (E)-Ajoene increases the number of cresyl violet-positive neurons and decreases the number of reactive gliosis in the CA1 region [1] .
    (E)-Ajoene
  • HY-P1387
    β-Amyloid (1-40) (rat)
    1 Publications Verification

    Amyloid-β Apoptosis Neurological Disease
    β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases 45Ca 2+ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease [1] .
    β-Amyloid (1-40) (rat)
  • HY-10932R

    nAChR iGluR Neurological Disease
    Aniracetam (Standard) is the analytical standard of Aniracetam. This product is intended for research and analytical applications. Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders [1] .
    Aniracetam (Standard)
  • HY-12882

    RC 61-91; NP-120

    iGluR Neurological Disease
    Ifenprodil (RC 61-91) is a noncompetitive NMDA receptor antagonist with anti-excitotoxic activity. Ifenprodil significantly improves long-term sensorimotor and spatial learning deficits in mice after acute subarachnoid hemorrhage. Ifenprodil reduces neuronal cell death in the basal cortex and CA1 region of the hippocampus induced by experimental subarachnoid hemorrhage. Ifenprodil attenuates Ca2+ overload in basal cortical cells and mitochondria, as well as brain edema in blood-brain barrier damage and early brain injury. Ifenprodil reduces the intracellular Ca2+ increase and apoptosis of primary cortical neurons under conditions of high glutamate concentrations. Ifenprodil also reduces the increase in endothelial permeability caused by high glutamate concentrations in human brain microvascular endothelial cells. Ifenprodil also inhibits GIRK channels and interacts with α1-adrenergic, 5-HT, and σ receptors [1].
    Ifenprodil
  • HY-159870

    Biochemical Assay Reagents Others
    E12CA1A3 is a lipid transfection reagent that boosts the delivery efficiency of mRNA [1].
    E12CA1A3
  • HY-116431

    Prostaglandin Receptor Cardiovascular Disease Neurological Disease
    I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle [1]. I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons .
    I-BOP
  • HY-100606

    (-)-Pindolol; (S)-(-)-Pindolol; S-Pindolol

    5-HT Receptor Adrenergic Receptor Neurological Disease
    l-Pindolol ((-)-pindolol) is a reversible, competitive and orally active 5-HT1A/1B antagonist. l-Pindolol is a partial β-adrenoceptor agonist. l-Pindolol can be used for the research of neurological disease [1] .
    l-Pindolol
  • HY-P3914

    Oct-CA(1-7)M(2-9)

    Bacterial Infection
    Cecropin A (1-7)-Melittin A (2-9) is an antimicrobial peptide with antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative aerobic bacteria, as well as antimalarial activity, without the adverse hemolytic properties of bee venom peptides [1].
    Cecropin A (1-7)-Melittin A (2-9)
  • HY-B0764
    Bucladesine sodium
    Maximum Cited Publications
    28 Publications Verification

    Dibutyryl CAMP sodium salt; DBCAMP sodium salt

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing [1] .
    Bucladesine sodium
  • HY-B0764R

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    Bucladesine (sodium) (Standard) is the analytical standard of Bucladesine (sodium). This product is intended for research and analytical applications. Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing [1] .
    Bucladesine sodium (Standard)
  • HY-103502
    CGP7930
    1 Publications Verification

    GABA Receptor Neurological Disease
    CGP7930 (3-(3’,5’-Di-tert-butyl-4’-hydroxy) phenyl-2, 2-dimethylpropanol) is a positive metabotropic GABAB receptor allosteric modulator. CGP7930 enhances the inhibitory effect of l-baclofen on the oscillatory activity of cultured cortical neurons [1].
    CGP7930

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: